SG11201901320WA - PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS - Google Patents
PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERSInfo
- Publication number
- SG11201901320WA SG11201901320WA SG11201901320WA SG11201901320WA SG11201901320WA SG 11201901320W A SG11201901320W A SG 11201901320WA SG 11201901320W A SG11201901320W A SG 11201901320WA SG 11201901320W A SG11201901320W A SG 11201901320WA SG 11201901320W A SG11201901320W A SG 11201901320WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- treatment
- blood cancers
- suite
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662376749P | 2016-08-18 | 2016-08-18 | |
| PCT/US2017/047578 WO2018035446A1 (en) | 2016-08-18 | 2017-08-18 | PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901320WA true SG11201901320WA (en) | 2019-03-28 |
Family
ID=61197183
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202101501PA SG10202101501PA (en) | 2016-08-18 | 2017-08-18 | PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS |
| SG11201901320WA SG11201901320WA (en) | 2016-08-18 | 2017-08-18 | PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202101501PA SG10202101501PA (en) | 2016-08-18 | 2017-08-18 | PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210379049A1 (ru) |
| EP (1) | EP3500268A4 (ru) |
| JP (2) | JP2019524888A (ru) |
| KR (1) | KR20190064573A (ru) |
| CN (1) | CN110461329A (ru) |
| AU (1) | AU2017313839A1 (ru) |
| BR (1) | BR112019003130A2 (ru) |
| CA (1) | CA3034258A1 (ru) |
| EA (1) | EA201990512A1 (ru) |
| MX (1) | MX2019001979A (ru) |
| SG (2) | SG10202101501PA (ru) |
| WO (1) | WO2018035446A1 (ru) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018507914A (ja) | 2015-03-09 | 2018-03-22 | インテクリン・セラピューティクス・インコーポレイテッド | 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法 |
| JP2020515639A (ja) | 2017-04-03 | 2020-05-28 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト |
| WO2020243058A1 (en) * | 2019-05-30 | 2020-12-03 | Coherus Biosciences, Inc. | Compositions and methods to treat cancer |
| JP2022104747A (ja) * | 2020-12-29 | 2022-07-11 | 国立研究開発法人国立がん研究センター | 抗ウイルス剤 |
| JP2022104746A (ja) * | 2020-12-29 | 2022-07-11 | 国立研究開発法人国立がん研究センター | 抗がん剤 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3018186B1 (ja) * | 1999-03-09 | 2000-03-13 | 大阪大学長 | 抗炎症剤、単球系細胞の増殖抑制剤 |
| US7223761B2 (en) * | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| JP2010265216A (ja) * | 2009-05-14 | 2010-11-25 | Takeda Chem Ind Ltd | 複素環化合物 |
| BR112015018048A2 (pt) * | 2013-01-30 | 2020-01-28 | Intekrin Therapeutics Inc | agonistas de ppary para tratamento de esclerose múltipla |
| WO2017211830A1 (en) * | 2016-06-08 | 2017-12-14 | Support-Venture Gmbh | Pharmaceutical combinations for treating cancer |
-
2017
- 2017-08-18 CN CN201780063382.4A patent/CN110461329A/zh active Pending
- 2017-08-18 AU AU2017313839A patent/AU2017313839A1/en not_active Abandoned
- 2017-08-18 EP EP17842202.8A patent/EP3500268A4/en not_active Withdrawn
- 2017-08-18 MX MX2019001979A patent/MX2019001979A/es unknown
- 2017-08-18 US US16/326,018 patent/US20210379049A1/en not_active Abandoned
- 2017-08-18 EA EA201990512A patent/EA201990512A1/ru unknown
- 2017-08-18 BR BR112019003130-8A patent/BR112019003130A2/pt unknown
- 2017-08-18 JP JP2019530367A patent/JP2019524888A/ja active Pending
- 2017-08-18 WO PCT/US2017/047578 patent/WO2018035446A1/en unknown
- 2017-08-18 SG SG10202101501PA patent/SG10202101501PA/en unknown
- 2017-08-18 CA CA3034258A patent/CA3034258A1/en active Pending
- 2017-08-18 KR KR1020197007705A patent/KR20190064573A/ko not_active Application Discontinuation
- 2017-08-18 SG SG11201901320WA patent/SG11201901320WA/en unknown
-
2022
- 2022-06-06 JP JP2022091309A patent/JP2022116304A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA3034258A1 (en) | 2018-02-22 |
| KR20190064573A (ko) | 2019-06-10 |
| CN110461329A (zh) | 2019-11-15 |
| EP3500268A4 (en) | 2020-04-15 |
| JP2022116304A (ja) | 2022-08-09 |
| EP3500268A1 (en) | 2019-06-26 |
| EA201990512A1 (ru) | 2019-08-30 |
| WO2018035446A1 (en) | 2018-02-22 |
| JP2019524888A (ja) | 2019-09-05 |
| SG10202101501PA (en) | 2021-03-30 |
| US20210379049A1 (en) | 2021-12-09 |
| AU2017313839A1 (en) | 2019-03-07 |
| BR112019003130A2 (pt) | 2019-05-21 |
| MX2019001979A (es) | 2019-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| SG11201901320WA (en) | PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201407900WA (en) | Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof | |
| SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201900043TA (en) | Antibody formulations | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201408171SA (en) | Fbxo3 inhibitors | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201810940XA (en) | Methods of treating pancreatic cancer |